Last updated: 11/03/2018 16:15:03
Drug Use Investigation for Arepanrix® (H1N1)
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Trial overview
Official title: Drug Use Investigation for Arepanrix® (H1N1)
Trial description: This post-marketing surveillance study is designed to collect safety information such as post-vaccination adverse events and adverse reactions from recipients of Arepanrix® (H1N1) Intramuscular Injection. The following items will be investigated as priority investigation items.<Priority investigation items>1) Allergic reactions2) Anaphylaxis
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
The number of recipients who have adverse reactions after injection
Timeframe: 29 days
The number of recipients who have post-vaccination adverse events after injection
Timeframe: 29 days
The number of recipients who have allergic reactions after injection
Timeframe: 29 days
The number of recipients who have anaphylaxis after injection
Timeframe: 29 days
Secondary outcomes:
Not applicable
Interventions:
Biological/vaccine: Arepanrix®
Enrollment:
3405
Observational study model:
Other
Primary completion date:
Not applicable
Time perspective:
Prospective
Clinical publications:
Suminobu Ito et al. (2013) Post-marketing Surveillance of AS03-adjuvanted Influenza (H1N1) Vaccine in Japan. Pharma Medica. 31(4):135-141.
Medical condition
Influenza
Product
GSK2340274A
Collaborators
Not applicable
Study date(s)
February 2010 to October 2010
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
Not applicable
Accepts healthy volunteers
Yes
- Subjects who receive Arepanrix® intramuscular injection for the first time
- Not applicable
Inclusion and exclusion criteria
Inclusion criteria:
- Subjects who receive Arepanrix® intramuscular injection for the first time
Exclusion criteria:
- Not applicable
Trial location(s)
No location data available.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Finalized
Actual primary completion date
Not applicable
Actual study completion date
2010-29-10
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website